J
José Luís Passos-Coelho
Researcher at Instituto Português de Oncologia Francisco Gentil
Publications - 52
Citations - 1582
José Luís Passos-Coelho is an academic researcher from Instituto Português de Oncologia Francisco Gentil. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 20, co-authored 45 publications receiving 1419 citations. Previous affiliations of José Luís Passos-Coelho include Nova Southeastern University & Johns Hopkins University.
Papers
More filters
Journal ArticleDOI
The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct anti-tumour activity in breast cancer.
Robert E. Coleman,Matthew C Winter,David Cameron,Richard Bell,David Dodwell,M. Keane,M. Gil,Diana Ritchie,José Luís Passos-Coelho,Duncan Wheatley,Roger Burkinshaw,S J Marshall,H. Thorpe +12 more
TL;DR: A retrospective evaluation of the AZURE trial data suggests a possible direct anti-tumour effect of ZOL in combination with CT, warranting formal evaluation in prospective studies.
Journal ArticleDOI
The benefit of HER2-targeted therapies on overall survival of patients with metastatic HER2-positive breast cancer – a systematic review
Diogo Mendes,Carlos Alves,Noemia Afonso,Fatima Cardoso,José Luís Passos-Coelho,Luis Costa,Sofia Andrade,Francisco Batel-Marques +7 more
TL;DR: HER2-directed therapies had an undeniable beneficial impact on the OS of patients with HER2+ mBC and are associated with a survival extent of more than 4.5 years, compared with a life expectancy of 1.5–years achieved 14 years ago.
Journal ArticleDOI
The aggressiveness of cancer care in the last three months of life: a retrospective single centre analysis.
Sofia Braga,Ana Miranda,Rute Fonseca,José Luís Passos-Coelho,Aires Fernandes,José Duro da Costa,António Moreira +6 more
TL;DR: Evaluated the use of chemotherapy in the last three months of life in a cohort of adult patients with advanced solid tumours with concerns that terminally ill patients are over treated with chemotherapy, even when such treatment is unlikely to palliate symptoms.
Journal Article
Nonlinear Pharmacokinetics of Cyclophosphamide in Patients with Metastatic Breast Cancer Receiving High-Dose Chemotherapy followed by Autologous Bone Marrow Transplantation
T L Chen,José Luís Passos-Coelho,Dennis A. Noe,M J Kennedy,K. C. Black,O. M. Colvin,Louise B. Grochow +6 more
TL;DR: The pharmacokinetics of cyclophosphamide has been evaluated in 15 patients with metastatic breast cancer undergoing high-dose chemotherapy with alkylating agents followed by autologous bone marrow transplantation, and a decline in concentration following attainment of an initial steady state was demonstrated.
Journal ArticleDOI
Predictive factors for peripheral-blood progenitor-cell collections using a single large-volume leukapheresis after cyclophosphamide and granulocyte-macrophage colony-stimulating factor mobilization.
José Luís Passos-Coelho,Hayden G. Braine,J. M. Davis,A M Huelskamp,K G Schepers,Karen Ohly,B Clarke,Susan K. Wright,S. J. Noga,Nancy E. Davidson +9 more
TL;DR: Reinfusion of PBPC collected in a single leukapheresis accelerates engraftment in the majority of patients, and bone marrow CD34+ cell content determines PBPC mobilization capacity and may help select hematopoietic rescue strategies.